Table 1 Background data for all patients analysed per modified intention to treata

From: Efficacy of clindamycin and LACTIN-V for in vitro fertilization patients with vaginal dysbiosis: a randomised double-blind, placebo-controlled multicentre trial

 

Clindamycin/LACTIN-V (N = 94)

Clindamycin/Placebo (N = 88)

Placebo/Placebo (N = 84)

P-value

Age

31.5 (4.7)

31.8 (4.5)

31.4 (4.7)

0.88

BMI

24.4 (3.7)

25.3 (4.1)

25.2 (4.6)

0.26

Infertility years

2.2 (1.7)

2.3 (1.6)

2.2 (1.5)

0.99

Primary infertility

61 (65%)

52 (59%)

58 (69%)

0.44

Antibiotics within one month from randomization

0

2 (2%)

1 (1%)

0.41

Tubal factor

7 (7%)

13 (15%)

10 (12%)

0.29

Male factor

38(40%)

45 (51%)

43 (51%)

0.26

Idiopathic

35 (37%)

24 (27%)

22 (26%)

0.20

Anovulation/ovarian

10 (11%)

5 (6%)

5 (6%)

0.36

Endometriosis

2 (2%)

4 (5%)

2 (2%)

0.67

Other

14 (15%)

7 (8%)

11 (13%)

0.33

Non-Caucasian ethnicity

5 (5%)

7 (8%)

5 (6%)

0.82

Vaginal douching

18 (19%)

26 (30%)

17 (20%)

0.20

Smoking prior to IVF

8 (9%)

6 (7%)

3 (4%)

0.36

Randomized in FET cycle

9 (10%)

12 (14%)

11 (13%)

0.69

Follicles at oocyte retrieval

11.0 (6.6)

11.6 (5.3)

10.9 (5.6)

0.75

Oocytes retrieved

9.2 (5.4)

10.1 (4.7)

8.9 (4.7)

0.29

Antibiotics at oocyte retrieval

3 (3%)

4 (5%)

7 (8%)

0.35

FET

25 (27%)

24 (27%)

23 (27%)

1.00

Double embryo transfer

1 (1%)

1 (1%)

3 (4%)

0.45

Blastocyst transfer

81 (86%)

79 (90%)

75 (89%)

0.77

  1. Data are shown as mean (SD) for continuous data and n (%) for categorical data.
  2. aAll patients with an embryo transfer less than 63 days from the active treatment start to cycle day 1 in the same menstrual cycle that the embryo transfer was performed.
  3. BMI Body mass index, FET Frozen embryo transfer.